• 𝗦𝗣𝗘𝗖𝗧𝗥𝗔 𝗙𝗢𝗥 𝗗𝗢𝗚𝗦 𝟯.𝟱–𝟳.𝟱 𝗞𝗚 (𝗔𝗳𝗼𝘅𝗼𝗹𝗮𝗻𝗲𝗿 + 𝗠𝗶𝗹𝗯𝗲𝗺𝘆𝗰𝗶𝗻 𝗢𝘅𝗶𝗺𝗲): 𝗔 𝗖𝗼𝗺𝗯𝗶𝗻𝗮𝘁𝗶𝗼𝗻 𝗔𝗻𝘁𝗶𝗽𝗮𝗿𝗮𝘀𝗶𝘁𝗶𝗰 𝗠𝗲𝗱𝗶𝗰𝗶𝗻𝗲
SPECTRA FOR DOGS 3.5–7.5 KG is a veterinary antiparasitic chewable tablet containing afoxolaner and milbemycin oxime. This weight-specific presentation is intended for dogs weighing more than 3.5 kg and up to 7.5 kg, subject to the applicable product label. Afoxolaner is an isoxazoline ectoparasiticide used against susceptible fleas and ticks, while milbemycin oxime is a macrocyclic lactone with activity against susceptible nematode parasites.
The combination provides complementary parasite control and is also used as part of heartworm prevention programs when administered at the approved interval. The correct tablet strength should always be selected according to the dog's actual body weight. Veterinary advice is recommended for puppies, breeding animals, dogs with neurological disorders, or animals receiving other medications.
• 𝗞𝗲𝘆 𝗕𝗲𝗻𝗲𝗳𝗶𝘁𝘀 𝗼𝗳 𝗦𝗣𝗘𝗖𝗧𝗥𝗔 𝗙𝗢𝗥 𝗗𝗢𝗚𝗦 𝟯.𝟱–𝟳.𝟱 𝗞𝗚
1. Helps control susceptible flea infestations in dogs within the specified weight range.
2. Provides systemic activity against susceptible tick species.
3. Helps control susceptible gastrointestinal nematodes.
4. Supports heartworm prevention when administered according to the approved veterinary schedule.
5. Combines external and internal parasite control in a convenient oral chewable formulation.
• 𝗛𝗼𝘄 𝗦𝗣𝗘𝗖𝗧𝗥𝗔 𝗙𝗢𝗥 𝗗𝗢𝗚𝗦 𝟯.𝟱–𝟳.𝟱 𝗞𝗚 𝗪𝗼𝗿𝗸𝘀
Afoxolaner acts primarily on ligand-gated chloride channels in arthropods, including GABA-gated and glutamate-gated chloride channels, disrupting normal neuronal signaling and causing paralysis and death of susceptible fleas and ticks. Milbemycin oxime increases chloride-ion permeability through glutamate-gated chloride channels in susceptible nematodes, producing neuromuscular paralysis. Together, these mechanisms provide activity against susceptible external and internal parasites while milbemycin oxime contributes to heartworm prevention by targeting developing heartworm larvae when used according to the approved regimen.
• 𝗨𝘀𝗮𝗴𝗲 𝗜𝗻𝘀𝘁𝗿𝘂𝗰𝘁𝗶𝗼𝗻𝘀 𝗳𝗼𝗿 𝗦𝗣𝗘𝗖𝗧𝗥𝗔 𝗙𝗢𝗥 𝗗𝗢𝗚𝗦 𝟯.𝟱–𝟳.𝟱 𝗞𝗚
1. Dosage: Use the presentation intended for dogs weighing more than 3.5 kg and up to 7.5 kg. The exact dose and treatment schedule should follow the approved product label.
2. Administration: Administer orally as a chewable tablet. Do not split, substitute, or combine tablet strengths unless specifically directed by a veterinarian.
3. Timing: For monthly parasite prevention, administer at the interval specified on the veterinary product label and maintain the schedule consistently.
4. Monitoring: Monitor the dog for treatment response and any unexpected reactions, particularly when initiating treatment or when the animal has underlying health conditions.
5. Precautions: Weigh the dog accurately before treatment and consult a veterinarian before use in very young, pregnant, lactating, debilitated, or neurologically affected dogs.
• 𝗠𝗲𝗱𝗶𝗰𝗶𝗻𝗮𝗹 𝗔𝗱𝘃𝗮𝗻𝘁𝗮𝗴𝗲𝘀 𝗼𝗳 𝗦𝗣𝗘𝗖𝗧𝗥𝗔 𝗙𝗢𝗥 𝗗𝗢𝗚𝗦 𝟯.𝟱–𝟳.𝟱 𝗞𝗚
1. Afoxolaner provides systemic protection against susceptible fleas and ticks.
2. Milbemycin oxime provides activity against susceptible gastrointestinal nematodes.
3. The combination offers coverage of multiple parasite groups with one oral veterinary product.
4. Regular administration can help maintain ongoing parasite prevention when used according to the approved schedule.
5. The weight-specific presentation allows appropriate dosing for dogs in the 3.5–7.5 kg body-weight range.
• 𝗢𝗳𝗳-𝗟𝗮𝗯𝗲𝗹 𝗨𝘀𝗲𝘀 𝗼𝗳 𝗦𝗣𝗘𝗖𝗧𝗥𝗔 𝗙𝗢𝗥 𝗗𝗢𝗚𝗦 𝟯.𝟱–𝟳.𝟱 𝗞𝗚
1. A veterinarian may consider alternative treatment approaches for susceptible parasitic conditions when supported by clinical evidence and professional judgment.
2. A veterinarian may use an active ingredient for a clinical situation that is not specifically listed on the local product label when appropriate.
3. Alternative dosing or treatment strategies may occasionally be considered when standard labelled treatment is unsuitable for an individual animal.
• 𝗘𝘅𝗽𝗲𝗿𝘁 𝗔𝗱𝘃𝗶𝗰𝗲 𝗳𝗼𝗿 𝗢𝗽𝘁𝗶𝗺𝗮𝗹 𝗨𝘀𝗲
1. Confirm the dog's current weight before selecting the 3.5–7.5 kg presentation.
2. Maintain the recommended dosing interval for continuous parasite prevention.
3. Do not give a different weight-band presentation without veterinary advice.
4. Inform the veterinarian about all medicines, supplements, and other antiparasitic products the dog receives.
5. Dogs with a history of seizures or neurological disorders should be assessed before receiving an isoxazoline-containing medicine.
6. Contact a veterinarian if significant vomiting, diarrhea, lethargy, tremors, ataxia, seizures, or other unexpected signs occur after administration.
• 𝗣𝗿𝗲𝗰𝗮𝘂𝘁𝗶𝗼𝗻𝘀
• 𝗖𝗮𝗿𝗱𝗶𝗼𝘃𝗮𝘀𝗰𝘂𝗹𝗮𝗿 𝗛𝗲𝗮𝗹𝘁𝗵
Dogs with significant cardiovascular disease should receive veterinary assessment before starting or changing parasite-control treatment. Heartworm prevention is important in at-risk dogs, but suspected established heartworm infection requires veterinary diagnosis and management rather than relying on preventive treatment alone.
• 𝗟𝗶𝘃𝗲𝗿 & 𝗞𝗶𝗱𝗻𝗲𝘆 𝗙𝘂𝗻𝗰𝘁𝗶𝗼𝗻
Dogs with significant liver or kidney impairment should be evaluated by a veterinarian before treatment. The veterinarian can consider the animal's overall health, concurrent medicines, and the approved product information when determining suitability.
• 𝗣𝗿𝗲𝗴𝗻𝗮𝗻𝗰𝘆 & 𝗕𝗿𝗲𝗮𝘀𝘁𝗳𝗲𝗲𝗱𝗶𝗻𝗴
Use during pregnancy or lactation should follow the specific product's approved veterinary information. Breeding animals should not receive treatment outside the labelled recommendations without veterinary guidance.
• 𝗗𝗿𝘂𝗴 𝗜𝗻𝘁𝗲𝗿𝗮𝗰𝘁𝗶𝗼𝗻𝘀
Tell the veterinarian about all prescription medicines, supplements, and antiparasitic products being used. Avoid combining multiple parasite treatments unless their concurrent use has been considered appropriate by a veterinary professional.
• 𝗘𝘅𝗶𝘀𝘁𝗶𝗻𝗴 𝗠𝗲𝗱𝗶𝗰𝗮𝗹 𝗖𝗼𝗻𝗱𝗶𝘁𝗶𝗼𝗻𝘀
Dogs with previous seizures or neurological disease should be evaluated before treatment because isoxazoline-class products, including afoxolaner, have been associated with neurological adverse reactions such as tremors, ataxia, and seizures in some animals.
• 𝗦𝘁𝗼𝗿𝗮𝗴𝗲 𝗜𝗻𝘀𝘁𝗿𝘂𝗰𝘁𝗶𝗼𝗻𝘀
1. Store according to the manufacturer's labelled storage requirements.
2. Keep the chewable tablets in their original packaging until administration.
3. Protect the medicine from excessive heat, moisture, and direct sunlight.
4. Keep the product out of reach of children and animals for which it was not intended.
5. Do not use the product after its expiry date or if the packaging is damaged.
• 𝗙𝗿𝗲𝗾𝘂𝗲𝗻𝘁𝗹𝘆 𝗔𝘀𝗸𝗲𝗱 𝗤𝘂𝗲𝘀𝘁𝗶𝗼𝗻𝘀 (𝗙𝗔𝗤𝘀)
• Q: What is SPECTRA FOR DOGS 3.5–7.5 KG?
A: SPECTRA FOR DOGS 3.5–7.5 KG is a veterinary antiparasitic chewable tablet containing afoxolaner and milbemycin oxime for dogs weighing more than 3.5 kg and up to 7.5 kg, according to the applicable product label.
• Q: What are the active ingredients in SPECTRA FOR DOGS?
A: The active ingredients are afoxolaner and milbemycin oxime. The exact strength should be confirmed from the manufacturer's packaging and locally approved product information.
• Q: What parasites does SPECTRA FOR DOGS help control?
A: Depending on the approved indication, the combination provides activity against susceptible fleas, ticks, gastrointestinal nematodes, and contributes to heartworm prevention.
• Q: How often is SPECTRA FOR DOGS administered?
A: For indications requiring ongoing prevention, it is generally administered once monthly according to the approved veterinary dosing schedule.
• Q: Can SPECTRA FOR DOGS be given to puppies?
A: Puppy eligibility depends on age, body weight, health status, and the local product label. A veterinarian should confirm whether the product is appropriate for a particular puppy.
• Q: Can SPECTRA FOR DOGS be used in dogs with seizures?
A: Dogs with a history of seizures or neurological disorders should be evaluated by a veterinarian before treatment because neurological adverse reactions have been reported with isoxazoline-class medicines.
• Q: Is SPECTRA FOR DOGS a prescription medicine?
A: Regulatory status varies between countries and jurisdictions. Follow the applicable local veterinary prescription, dispensing, and administration requirements.
